

resources and further focus. Our continual approach to engineer our own innovative, highly selective drug candidates has delivered several medicines with enhanced selectivity and limited off-target activity, allowing sustained target inhibition and flexibility for use as part of combination therapies. We also gained substantial knowledge of these oncogenic pathways, and the issues involved in addressing them. In contrast to traditional cytotoxin-based ADCs, we believe that our antibody-targeted therapy synergistic approach may also be combinable with immunotherapy- or chemotherapy-based frontline standards of care, could overcome chemotherapy resistance, and could avoid cytotoxin-related toxicities that limit long-term administration. This platform also maximizes on our long history of addressing patients with genetic drivers, who benefit less from traditional ADC therapies. All transaction-related figures stated in US dollars (US\$) are included for illustrative purposes only, and are based on an assumed exchange rate of US\$1:RMB7.36. All cash considerations will be denominated in Renminbi (RMB). About HUTCHMEDHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. About Shanghai PharmaShanghai Pharma (www.sphchina.com) is a national integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical production and distribution markets. Shanghai Pharma's business mainly covers two segments, namely, pharmaceutical industry and pharmaceutical business. The A shares and H shares of Shanghai Pharma are listed on the Shanghai Stock Exchange (stock code:601607) and the Hong Kong Stock Exchange (stock code:02607), respectively. About GP Health Service CapitalGP Health Service Capital is a professional fund management company committed to industrial investment, mergers and acquisitions and integrations in the medical and health field. Its largest shareholder is GP Capital. It is incorporated under the laws of the PRC with limited liability.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including, without limitation, statements concerning: HUTCHMED's future plans and prospects, its expectations as to the anticipated amount of proceeds, the intended use of proceeds, the anticipated closing date of the proposed transactions, and the therapeutic potential and clinical development of its R&D programs as well as the safety, efficacy, tolerability, scalability or combinability of all candidates under such programs. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the considerations, satisfaction of the conditions precedent to the consummation of the proposed transactions (including the ability of the parties to secure regulatory approvals on the terms expected, at all or in a timely manner), the ability of the parties to complete the proposed transaction, the continued sufficiency of preclinical and clinical data to support development and approval of the R&D programs in China, in the United States and in other jurisdictions, their potential to gain clinical trial approvals from regulatory authorities, the safety profile of the R&D programs, HUTCHMED ability to fund, implement and complete its further clinical development and commercialization plans for the R&D programs, the timing of these events; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC programs; and HUTCHMED's ability to successfully develop and commercialize the R&D programs. In addition, when or if used herein, the words and phrases "aims," "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "on track," "predicts," "plans," "potential," "promising," "should," "to be," "will," and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Forward-looking statements are neither historical facts nor assurances of future performance. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

Inside Information

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018). CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick Zhou +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 / HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 / Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500 / EX-99.2 3 hcm-20250102xex99d2.htm EX-99.2 Exhibit 99.2 Overseas Regulatory Announcement Disposal Transaction HUTCHMED (China) Limited (HUTCHMED) notes the below text, which is from an announcement released to the Stock Exchange of Hong Kong Limited on January 1, 2025 pursuant to Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. As described in the HUTCHMED announcement entitled "HUTCHMED Announces US\$608 million Divestment of Non-Core Joint Venture", the text relates to the proposed disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. About HUTCHMEDHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS Investor Enquiries

TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON

PHARMACEUTICALS LIMITEDâ€¢ the Seller (a wholly-owned subsidiary of the Company) entered into: (i) a major transaction of the Company and is subject to the reporting, announcement, circular and shareholdersâ€™ approval requirements under Chapter 14 of the Listing Rules.â€¢ (ii) B. The GP Health SPA â€” Right to Designate Purchaser for the GP Health Sale Sharesâ€¢ below), the Circular is expected to be dispatched to the Shareholders on or before January 28, 2025.â€¢ www.hutch

the Circular is expected to be dispatched to the shareholders of the Seller on or before January 10, 2024 at www.wintonmed.com/event in due course. **INTRODUCTION** On December 31, 2024, the Seller (a wholly-owned subsidiary of the Company) entered into: (iii) the GP Health SPA with GP Health Service Capital relating to the disposal of the GP Health Sale Shares, representing 35% equity interest in SHPL, for an aggregate purchase price of RMB3,482,627,982 (approximately US\$473 million); and (iv) the Shanghai Pharma SPA with Shanghai Pharma relating to the disposal of the Shanghai Pharma Sale Shares, representing 10% equity interest in SHPL, for an aggregate purchase price of RMB995,036,566 (approximately US\$135 million). As of the date of the Agreements, SHPL, which operates its own-brand prescription drug business, is held as to 50% by the Seller and 50% by Shanghai TCM, and is a non-consolidated joint venture of the Company. Immediately upon the completion of the Proposed Disposal, the Company will retain an indirect 5% equity interest in SHPL. **REASONS FOR AND BENEFITS OF THE**

Disposal, the Company will retain an indirect 5% equity interest in SHPL. **REASONS FOR, AND BENEFITS OF, THE PROPOSED DISPOSAL** As the core business of the Group is the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases including the advancement of next-generation antibody-targeted-therapy conjugate programs, the Proposed Disposal will further optimize the Group's capital and debt structure (including improving its cash balance and reducing its onshore liability level) by monetizing the underlying value of the SHPL joint venture, which operates its own-brand prescription drug business, and allowing the Group to focus resources on its core business areas. Based on the

above, the Directors consider that the terms of the Agreements and the transactions contemplated thereunder are fair and reasonable and in the interests of the Company and the Shareholders as a whole.â€¢**IMPLICATIONS UNDER THE LISTING RULES**â€¢As the highest applicable percentage ratio in respect of the Proposed Disposal exceeds 25% but is less than 75%, the Proposed Disposal constitutes a major transaction of the Company and is subject to the reporting, announcement, circular and shareholdersâ€™ approval requirements under Chapter 14 of the Listing Rules.â€¢â€¢**EGM AND CIRCULAR**â€¢An EGM will be convened to consider and, if thought fit, to approve the transactions contemplated

AND CIRCULAR AT THE EGM will be convened to consider and, if thought fit, to approve the transactions contemplated under the Agreements, including the Proposed Disposal. All Shareholders who have a material interest (which is different from all other Shareholders) in any of the transactions contemplated under the Agreements, including the Proposed Disposal, and their associates (as defined in the Listing Rules) will be required to abstain from voting on the resolution to approve the transactions contemplated under the Agreements, including the Proposed Disposal, at the EGM. The Circular containing, among other things, (i) further details on the terms of the Proposed Disposal; and (ii) other information as required under the Listing Rules together with a notice convening the EGM will be disseminated to

other information as required under the Listing Rules together with a notice convening the EGM, will be dispatched to the Shareholders in due course. As additional time is required to allow for GP Health Service Capital to designate the GP Purchaser Fund and the Designated Purchaser to purchase all or part of the GP Health Sale Shares and for the share purchase agreements to be entered into on or before January 17, 2025 (or such other date before Closing as agreed by the Seller), or procure the GP Purchaser Funds to purchase any remaining undesignated GP Health Sale Shares and enter into share purchase agreements (as described in the section headed "B. The GP Health SPA")

Right to Designate Purchaser for the GP Health Sale Sharesâ€ below), the Circular is expected to be dispatched to the Shareholders on or before January 28, 2025.â€ The Company will host a short update call on Tuesday, January 7, 2025. Details will be available at www.hutch-med.com/event in due course.â€ The Proposed Disposal is subject to all of the conditions under the Agreements being satisfied (or, if applicable, waived) and therefore may or may not become unconditional. If any of the conditions under the Agreements is not satisfied (or, if applicable, waived), the Proposed Disposal will not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the

shares and other securities of the Company. **A. INTRODUCTION** On December 31, 2024, the Seller (a wholly-owned subsidiary of the Company) entered into: (i) the GP Health SPA with GP Health Service Capital relating to the disposal of the GP Health Sale Shares, representing 35% equity interest in SHPL; and (ii) the Shanghai Pharma SPA with Shanghai Pharma relating to the disposal of the Shanghai Pharma Sale Shares, representing 10% equity interest in SHPL. As of the date of the Agreements, SHPL, which operates its own-brand prescription drug business, is held as to 50% by the Seller and 50% by Shanghai TCM, and is a non-consolidated joint venture of the Company. Immediately upon the completion of the Proposed Disposal, the Company will retain an indirect 5% equity interest in SHPL. **B. THE GP HEALTH SPA** The principal terms of the GP Health SPA are set out.

below: (i) the Seller (as seller); and (ii) GP Health Service Capital (as purchaser). To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, GP Health Service Capital and its ultimate beneficial owners are third parties independent of the Company and its connected persons. (b) Subject Matter: The Seller agreed to sell, and GP Health Service Capital agreed to purchase, the GP Health Sale Shares, representing 35% equity interest in SHPL. (c) Right to Designate Purchaser for the GP Health Sale Shares: On or before January 17, 2025 (or such other date before Closing as agreed by the Seller), subject to the prior written consent by the Seller, GP Health Service Capital has the right to designate (i) a fund established by GP Health Service Capital as manager and one of the general partners (the "GP Purchaser Fund"), and (ii) another designated party (the "Designated Purchaser") to purchase all or part of the GP Health Sale Shares. Upon designation by GP Health Service Capital, the Designated Purchaser will purchase no more than 10% equity interest in SHPL from the GP Health Sale Shares and the remaining GP Health Sale Shares will be purchased by the GP Purchaser Fund, subject to the following conditions: (i) each of the GP Purchaser Fund, the Designated

Purchaser and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons; (ii) on or before January 17, 2025 (or such other date before Closing as agreed by the Seller), the Seller and GP Health Service Capital will enter into a share purchase agreement on substantially the same terms as the GP Health SPA (save for the right to designate other purchasers) with each of the GP Purchaser Fund and the Designated Purchaser, and each of the GP Purchaser Fund and the Designated Purchaser will assume the respective rights and obligations of GP Health Service Capital under the GP Health SPA corresponding to the proportionate equity interest in SHPL they will purchase; and (iii) the GP Health SPA will be amended in accordance with such designation. If GP Health Service Capital does not designate and enter into the share purchase agreements referred to above in respect of all of the GP Health Sale Shares on or before January 17, 2025 (or such other date before Closing as agreed by the Seller), GP Health Service Capital will procure the GP Purchaser Fund and/or one or more new funds established by GP Health Service Capital as manager and one of the general partners (together with the GP Purchaser Fund, the "GP Purchaser Funds") to purchase the remaining undesignated GP Health Sale Shares, subject to all of the conditions referred to above. Further announcement(s) containing details of the GP Purchaser Funds and the Designated Purchaser will be made by the Company as and when the GP Purchaser Funds and the Designated Purchaser have been designated by GP Health Service Capital and share purchase agreements are entered into with the GP Purchaser Funds and the Designated Purchaser. Consideration: The aggregate purchase price for the GP Health Sale Shares is RMB3,482,627,982 (approximately US\$473 million). The aggregate purchase price (after deducting withholding tax) is payable in cash by GP Health Service Capital to an escrow account jointly managed by the Seller and GP Health Service Capital on the date of Closing. Upon the obtaining of all necessary approvals from relevant government authorities after the date of Closing, the aggregate purchase price (after deducting withholding tax) paid by GP Health Service Capital will be released for remittance to an offshore bank account designated by the Seller. The purchase price was determined after arm's length negotiations between the parties with reference to SHPL's consolidated net profit for the year ended December 31, 2023 attributable to the GP Health Sale Shares.

Profit Compensation: (i) Interim Profit Compensation: In the event that the actual net profit of SHPL for any year during the Profit Guarantee Period of the years ending December 31, 2024, 2025, 2026 and 2027 (the "Actual Net Profit") is lower than the guaranteed net profit for the year of RMB663.0 million, RMB696.5 million, RMB731.0 million and RMB767.5 million respectively (the "Guaranteed Net Profit"), within 30 Business Days from the date when the annual audit report of SHPL for the respective year is issued, the Seller is required to provide interim profit compensation to GP Health Service Capital (the "Interim Profit Compensation") in cash, in the amount calculated as follows: $A \times (B - C)$ in which A refers to the equity interest purchased by GP Health Service Capital pursuant to the GP Health SPA, B refers to the Guaranteed Net Profit for the year, and C refers to the Actual Net Profit for the year. (ii) Cumulative Profit Compensation: In the event that the actual cumulative net profit of SHPL for the Profit Guarantee Period (the "Actual Cumulative Net Profit") is lower than the guaranteed cumulative net profit of RMB2,858 million (the "Guaranteed Cumulative Net Profit"), within 30 Business Days from the date when the annual audit report for the year ending December 31, 2027 of SHPL is issued, the Seller is required to provide cumulative profit compensation to GP Health Service Capital (the "Cumulative Profit Compensation"), which may be settled in cash or in the form of equity interests in SHPL. If the Seller settles the Cumulative Profit Compensation in cash, the amount will be calculated as follows: $A \times (B / C - 1) - D$ in which A refers to the aggregate purchase price paid by GP Health Service Capital (i.e. RMB3,482,627,982), B refers to the Guaranteed Cumulative Net Profit, C refers to the Actual Cumulative Net Profit and D refers to any Interim Profit Compensation already paid. The Seller and GP Health Service Capital will further agree in writing in respect of any settlement of Cumulative Profit Compensation in the form of the transfer of equity interests in SHPL (or any other forms). If the Seller and GP Health Service Capital agree on the settlement of the compensation amount in the form of the transfer of equity interests in SHPL, the equity interest percentage to be transferred by the Seller to GP Health Service Capital will be calculated as follows: $A \times (B / C - 1) \times (1 - D / E)$ in which A refers to the equity interest purchased by GP Health Service Capital pursuant to the GP Health SPA, B refers to the Guaranteed Cumulative Net Profit, C refers to the Actual Cumulative Net Profit, D refers to any Interim Profit Compensation already paid and any Cumulative Profit Compensation already settled in cash, and E refers to the amount of Cumulative Profit Compensation to be settled in cash before deduction of any Interim Profit Compensation already paid. The Seller shall provide the Interim Profit Compensation and/or the Cumulative Profit Compensation to GP Health Service Capital within 30 Business Days from the determination of the Interim Profit Compensation and/or the Cumulative Profit Compensation, except that if internal procedures including obtaining necessary shareholders' approval are required then the time required for such procedures will not count towards the 30 Business Days, but in any event the compensation shall be paid no later than 45 Business Days from the determination of the Interim Profit Compensation and/or the Cumulative Profit Compensation or such date as mutually agreed by the parties. Any Interim Profit Compensation and/or Cumulative Profit Compensation payable by the Seller during the Profit Guarantee Period will first be offset against the Seller's portion of the undistributed profit or loss of SHPL prior to Closing. Please refer to "Pre-Closing Profit or Loss Allocation" below for further details.

The aggregate cash-equivalent amount of the Interim Profit Compensation and the Cumulative Profit Compensation will not exceed RMB696 million. Operation and Management of SHPL during the Transition Period: The parties have agreed that during the Transition Period, the Seller has the right to recommend the general manager of SHPL (who is the core management personnel responsible for all production operation and management activities of SHPL) for nomination by Shanghai Pharma and appointment by the board of directors of SHPL. In addition, the board of directors of SHPL has approved the financial budget for the year ending December 31, 2025 and the principles of the financial budget for the years ending December 31, 2026 and 2027, including the targets for net profit of SHPL which are no less than the Guaranteed Net Profit. Distribution of Retained Earnings of SHPL: On the date of Closing, the shareholders of SHPL will approve the distribution of retained earnings as of October 31, 2024 of SHPL in the following manner: (i) on the date of Closing, retained earnings in the amount of RMB414 million will be declared and become the entitlement of the existing shareholders of SHPL, being the Seller and Shanghai TCM, in proportion to their respective shareholding percentage in SHPL before Closing (the "Attributed Retained Earnings"); and (ii) on the date of Closing, the remaining undistributed retained earnings in the amount of RMB423 million will be declared and become the entitlement of the then shareholders of SHPL immediately after Closing in proportion to their respective shareholding percentage in SHPL, and will be distributed to the then shareholders of SHPL no later than September 30, 2025. Pre-Closing Profit or Loss Allocation: On the date of Closing, the shareholders of SHPL will approve the allocation of profits or losses prior to Closing in the following manner: (i) the profits or losses generated by SHPL

during the period between November 1, 2024 and the earlier of (a) the date of Closing and (b) March 31, 2025 will be declared and become the entitlement of the existing shareholders of SHPL, being the Seller and Shanghai TCM, in proportion to their respective shareholding percentage in SHPL before Closing; and (ii) the profits or losses generated by SHPL during the period between April 1, 2025 and the date of Closing (if any) will be declared and become the entitlement of the then shareholders of SHPL immediately after Closing in proportion to their respective shareholding percentage in SHPL (collectively, the "Attributed Profit or Loss"). "Adjustable Retained Dividends" RMB315 million of the Seller's portion of the Attributed Retained Earnings and the Attributed Profit or Loss will be retained by SHPL as adjustable retained dividends (the "Seller's Adjustable Retained Dividends"). If the Seller is required to provide any Interim Profit Compensation or Cumulative Profit Compensation during the Profit Guarantee Period, the amount equivalent to the Interim Profit Compensation or Cumulative Profit Compensation payable will be deducted from the Seller's Adjustable Retained Dividends and be distributed to GP Health Service Capital instead. After the Profit Guarantee Period and the due settlement of any Interim Profit Compensation or Cumulative Profit Compensation by the Seller, the Seller's Adjustable Retained Dividends (subject to any adjustment referred to above) will be distributed to the Seller by no later than December 31, 2028. "Board Composition of SHPL" The board of directors of SHPL consists of seven directors, of which Shanghai Pharma has the right to nominate four directors, GP Health Service Capital has the right to nominate two directors and the Seller has the right to nominate one director. "Conditions" (i) Conditions to obligations of both the Seller and GP Health Service Capital: The obligations of both the Seller and GP Health Service Capital under the GP Health SPA are conditional upon (i) the simultaneous Closing of the Shanghai Pharma SPA, and (ii) the Company having obtained all necessary internal approvals and shareholders' approval with respect to the GP Health SPA. (ii) Conditions to the Seller's obligation to sell: The Seller's obligation to sell under the GP Health SPA is also conditional on the satisfaction or waiver (as applicable) of certain conditions, including (i) the obtaining of the necessary government approvals (including, if applicable, antitrust approvals) and the completion of the necessary governmental registration by GP Health Service Capital (including the necessary governmental registration to be completed by the GP Purchaser Fund and the Designated Purchaser), (ii) GP Health Service Capital having obtained all necessary internal approvals, (iii) the agreement among the then shareholders of SHPL immediately after Closing on arrangements concerning SHPL such as corporate governance, business development and shareholders' rights during the Transition Period, (iv) the agreement among the then shareholders of SHPL immediately after Closing on the distribution of retained earnings as of October 31, 2024 of SHPL and the allocation of profits or losses generated by SHPL prior to Closing, and (v) GP Health Service Capital having demonstrated it has sufficient funds to settle the purchase price and complete the transaction. (iii) Conditions to GP Health Service Capital's obligation to purchase: GP Health Service Capital's obligation to purchase under the GP Health SPA is also conditional on the satisfaction or waiver (as applicable) of certain conditions, including (i) the Seller having obtained all necessary internal approvals, (ii) the agreement among the then shareholders of SHPL immediately after Closing on arrangements concerning SHPL such as corporate governance, business development and shareholders' rights during the Transition Period, (iii) the agreement among the then shareholders of SHPL immediately after Closing on the distribution of retained earnings as of October 31, 2024 of SHPL and the allocation of profits or losses generated by SHPL prior to Closing, and (iv) there being no occurrence of events that could have any material adverse impact on SHPL and its development prospects. "Closing" Within two Business Days after the satisfaction or waiver (as applicable) of the conditions (other than conditions which can only be satisfied at Closing by nature), GP Health Service Capital will initiate, and complete on a best effort basis, the declaration of withholding taxes to the relevant tax authorities. "Closing" will take place (i) on the third Business Day after the issuance of certificate for withholding taxes by the relevant tax authorities; or (ii) such other date as may be agreed by the parties to the GP Health SPA. "Termination" Both parties have the right to terminate the GP Health SPA if any of the conditions are not satisfied or waived (as applicable) by the Longstop Date, provided that the failure to satisfy such condition is not caused or resulted from the failure of such party to perform any obligation under the GP Health SPA or within the control of such party. "The Seller" is entitled to unilaterally terminate the GP Health SPA prior to Closing by written notice to GP Health Service Capital in the event that GP Health Service Capital fails to pay the purchase price for the GP Health Sale Shares or settle the payment of withholding taxes in accordance with the GP Health SPA and fails to remedy such failure. Either party is entitled to unilaterally terminate the GP Health SPA if the other party materially breaches its warranty or other covenants or obligations under the GP Health SPA and fails to remedy such breach. "C. THE SHANGHAI PHARMA SPA" The principal terms of the Shanghai Pharma SPA are set out below: (i) Date: December 31, 2024. (ii) Parties: (i) the Seller (as seller); and (ii) Shanghai Pharma (as purchaser). "To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Shanghai Pharma and its ultimate beneficial owners are third parties independent of the Company and its connected persons." "Subject Matter" The Seller agreed to sell, and Shanghai Pharma agreed to purchase, the Shanghai Pharma Sale Shares, representing 10% equity interest in SHPL. "Consideration" The aggregate purchase price for the Shanghai Pharma Sale Shares is RMB995,036,566 (approximately US\$135 million). The aggregate purchase price (after deducting withholding tax) is payable in cash by Shanghai Pharma to an escrow account jointly managed by the Seller and Shanghai Pharma on the date of Closing. Upon the obtaining of all necessary approvals from relevant government authorities after the date of Closing, the aggregate purchase price (after deducting withholding tax) paid by Shanghai Pharma will be released for remittance to an offshore bank account designated by the Seller. "The purchase price was determined after arm's length negotiations between the parties with reference to SHPL's consolidated net profit for the year ended December 31, 2023 attributable to the Shanghai Pharma Sale Shares." "Operation and Management of SHPL during the Transition Period" The Seller and Shanghai Pharma agreed on the same arrangements concerning the operation and management of SHPL during the Transition Period under the GP Health SPA. Please refer to the section headed "B. The GP Health SPA" above for details. "Distribution of Retained Earnings of SHPL" The Seller and Shanghai Pharma agreed on the same arrangements concerning the distribution of retained earnings as of October 31, 2024 of SHPL under the GP Health SPA. Please refer to the section headed "B. The GP Health SPA" above for details. "Pre-Closing Profit or Loss Allocation" The Seller and Shanghai Pharma agreed on the same arrangements concerning the allocation of profits or losses generated by SHPL prior to Closing under the GP Health SPA. Please refer to the section headed "B. The GP Health SPA" above for details. "Board Composition of SHPL" The board of directors of SHPL consists of seven directors, of which Shanghai Pharma has the right to nominate four directors, GP Health Service Capital has the right to nominate two directors and

the Seller has the right to nominate one director.â€¢Conditionsâ€¢(i)Conditions to obligations of both the Seller and Shanghai Pharma â€¢The obligations of both the Seller and Shanghai Pharma under the Shanghai Pharma SPA are conditional upon (i) the simultaneous Closing of the GP Health SPA, (ii) the Company having obtained all necessary internal approvals and shareholdersâ€™ approval with respect to the Shanghai Pharma SPA, and (iii) the obtaining of the necessary government approvals (including antitrust approvals) and the completion of the necessary governmental registration by Shanghai Pharma. â€¢(ii)Conditions to the Sellerâ€™s obligation to sellâ€¢The Sellerâ€™s obligation to sell under the Shanghai Pharma SPA is also conditional on the satisfaction or waiver (as applicable) of certain conditions, including (i) Shanghai Pharma having obtained all necessary internal approvals, (ii) the partiesâ€™ agreement on arrangements concerning SHPL such as corporate governance, business development and shareholdersâ€™ rights during the Transition Period, (iii) the partiesâ€™ agreement on the distribution of retained earnings as of October 31, 2024 of SHPL and the allocation of profits or losses generated by SHPL prior to Closing, and (iv) affiliates of Shanghai Pharma having irrevocably agreed to waive their right of first refusal to purchase 35% equity interest in SHPL. â€¢â€¢(iii)Conditions to Shanghai Pharmaâ€™s obligation to purchaseâ€¢Shanghai Pharmaâ€™s obligation to purchase under the Shanghai Pharma SPA is also conditional on the satisfaction or waiver (as applicable) of certain conditions, including (i) the Seller having obtained all necessary internal approvals, and (ii) there being no occurrence of events that could have any material adverse impact on SHPL and its development prospects.

â€¢Closingâ€¢Within two Business Days after the satisfaction or waiver (as applicable) of the conditions (other than conditions which can only be satisfied at Closing by nature), Shanghai Pharma will initiate, and complete on a best effort basis, the declaration of withholding taxes to the relevant tax authorities, provided that the Seller has provided all required information of the Seller to Shanghai Pharma. â€¢Closing will take place (i) on the third Business Day after the issuance of certificate for withholding taxes by the relevant tax authorities; or (ii) such other date as may be agreed by the parties to the Shanghai Pharma SPA. â€¢Terminationâ€¢Both parties have the right to terminate the Shanghai Pharma SPA if any of the conditions are not satisfied or waived (as applicable) by the Longstop Date, provided that the failure to satisfy such condition is not caused or resulted from the failure of such party to perform any obligation under the Shanghai Pharma SPA in time or within the control of such party. Â ªThe Seller is entitled to unilaterally terminate the Shanghai Pharma SPA prior to Closing by written notice to Shanghai Pharma in the event that Shanghai Pharma fails to pay the purchase price for the Shanghai Pharma Sale Shares or settle the payment of withholding taxes in accordance with the Shanghai Pharma SPA and fails to remedy such failure. Either party is entitled to unilaterally terminate the Shanghai Pharma SPA if the other party materially breaches its warranty or other covenants or obligations under the Shanghai Pharma SPA and fails to remedy such breach. â€¢D.REASONS FOR, AND BENEFITS OF, THE PROPOSED DISPOSALâ€¢As the core business of the Group is the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases including the advancement of next-generation antibody-targeted-therapy conjugate programs, the Proposed Disposal will further optimize the Groupâ€™s capital and debt structure (including improving its cash balance and reducing its onshore liability level) by monetizing the underlying value of the SHPL joint venture, which operates its own-brand prescription drug business, and allowing the Group to focus resources on its core business areas. â€¢Based on the above, the Directors consider that the terms of the Agreements and the transactions contemplated thereunder are fair and reasonable and in the interests of the Company and the Shareholders as a whole.â€¢The Company expects to record a gain on disposal of approximately US\$477 million before taxation based on the difference between the aggregate purchase price for the Sale Shares (taking into account the Companyâ€™s current estimate of the Interim Profit Compensation and Cumulative Profit Compensation as described in the section headed â€œB. The GP Health SPA â€” Profit Compensationâ€¢ above) and the carrying value of the Sale Shares representing the Sellerâ€™s investment in SHPL. The actual gain to be recorded by the Company is subject to review and audit, and therefore may vary from the amount mentioned above. â€¢â€¢â€¢The Company intends to use the proceeds from the Proposed Disposal to further develop its internal pipeline and drive its core business strategy forward. This pipeline and strategy include its next-generation antibody drug conjugate (â€œADCâ€) platform, which builds on the Companyâ€™s extensive knowledge from pursuing oncological pathways and proven expertise in small molecule targeted therapeutics. By combining antibodies with targeted therapeutics instead of cytotoxins, these antibody-targeted therapy conjugates (â€œATTCsâ€) offer dual mechanisms for addressing a target. Pre-clinical research has shown robust anti-tumor activity with durable response following a single administration, and stronger anti-tumor activity compared to administration with the individual antibody and targeted therapy components, improving tolerability associated with targeted therapy. The Company plans to move the first of these ATTCs into clinical trials in the second half of 2025.â€¢E.IMPLICATIONS UNDER THE LISTING RULESâ€¢As the highest applicable percentage ratio in respect of the Proposed Disposal exceeds 25% but is less than 75%, the Proposed Disposal constitutes a major transaction of the Company and is subject to the reporting, announcement, circular and shareholdersâ€™ approval requirements under Chapter 14 of the Listing Rules.â€¢F.INFORMATION ON THE PARTIES AND SHPLâ€¢(1)The Companyâ€¢The Company is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan.â€¢(2)GP Health Service Capital â€¢GP Health Service Capital is a company incorporated under the laws of the PRC with limited liability. Its largest shareholder is GP Capital. It is a professional fund management company committed to industrial investment, mergers and acquisitions and integrations in the medical and health field. â€¢(3)Shanghai Pharmaâ€¢Shanghai TCM is a wholly-owned subsidiary of Shanghai Pharma. â€¢Shanghai Pharma is a national integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical production and distribution markets. Shanghai Pharmaâ€™s business mainly covers two segments, namely, pharmaceutical industry and pharmaceutical business. The A shares and H shares of Shanghai Pharma are listed on the Shanghai Stock Exchange (stock code: 601607) and the Hong Kong Stock Exchange (stock code: 02607), respectively. â€¢(4)SHPLâ€¢SHPL is a company incorporated under the laws of the PRC with limited liability and is principally engaged in manufacturing, selling and distribution of prescription drug products. As of the date of the Agreements, SHPL is held as to 50% by the Seller and 50% by Shanghai TCM, and is a non-consolidated joint venture of the Company. Immediately upon the completion of the Proposed Disposal, the Company will retain an indirect 5% equity interest in SHPL (without taking into account any transfer of equity interest in SHPL for the settlement of any Cumulative Profit Compensation in the form of equity interest in SHPL, if so agreed between the Seller and GP Health Service Capital).â€¢Based on the audited consolidated financial statements of SHPL prepared in accordance with

International Financial Reporting Standards, the audited net profits before and after taxation of SHPL for the two years ended December 31, 2022 and 2023 are: $\text{€} 11,642,112,485$ Net profit before taxation $\text{€} 11,642,112,485$ Net profit after taxation $\text{€} 99,683,954,463$ The unaudited consolidated net asset value of SHPL as at June 30, 2024 was approximately US\$156.4 million.

G.RECOMMENDATION OF THE BOARDHaving taken into account the reasons for, and benefits of, the Proposed Disposal as set out above, the Directors have unanimously approved, among other things, the Proposed Disposal and recommend the Shareholders to vote in favour of the resolution to be proposed at the EGM to approve the transactions contemplated by the Agreements, including the Proposed Disposal.H. EGM AND CIRCULARAn EGM will be convened to consider and, if thought fit, to approve the transactions contemplated under the Agreements, including the Proposed Disposal. All Shareholders who have a material interest (which is different from all other Shareholders) in any of the transactions contemplated under the Agreements, including the Proposed Disposal, and their associates (as defined in the Listing Rules) will be required to abstain from voting on the resolution to approve the transactions contemplated under the Agreements, including the Proposed Disposal, at the EGM. The Circular containing, among other things, (i) further details on the terms of the Proposed Disposal; and (ii) other information as required under the Listing Rules together with a notice convening the EGM, will be dispatched to the Shareholders in due course. As additional time is required to allow for GP Health Service Capital to designate the GP Purchaser Fund and the Designated Purchaser to purchase all or part of the GP Health Sale Shares and for the share purchase agreements to be entered into on or before January 17, 2025 (or such other date before Closing as agreed by the Seller), or procure the GP Purchaser Funds to purchase any remaining undesignated GP Health Sale Shares and enter into share purchase agreements (as described in the section headed "B. The GP Health SPA's Right to Designate Purchaser for the GP Health Sale Shares" above), the Circular is expected to be dispatched to the Shareholders on or before January 28, 2025. The Proposed Disposal is subject to all of the conditions under the Agreements being satisfied (or, if applicable, waived) and therefore may or may not become unconditional. If any of the conditions under the Agreements is not satisfied (or, if applicable, waived), the Proposed Disposal will not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the shares and other securities of the Company.

I.DEFINITIONSIn this announcement, unless the context otherwise requires, the following expressions have the following meanings:the GP Health SPA and the Shanghai Pharma SPABusiness Daya day (other than a Saturday, Sunday or public holiday) on which banks in the PRC are generally open for businessCircularthe circular to be dispatched by the Company to the Shareholders in connection with the EGMClosingclosing of the Proposed Disposal in accordance with the terms of the AgreementsCompany HUTCHMED (China) Limited, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 13), the AIM market of the London Stock Exchange (stock code: HCM) and in the form of American depositary shares on the NASDAQ Global Select Market (ticker symbol: HCM)Directorsthe directors of the CompanyEGMthe extraordinary general meeting of the Company to be convened for the Shareholders to consider and, if thought fit, approve the transactions contemplated by the Agreements, including the Proposed Disposal and, if applicable, share purchase agreements with the GP Purchaser Funds and the Designated PurchaserGP Health Service CapitalGP Health Service Capital Co., Ltd.

(a) a company incorporated in the PRC with limited liability shares representing 35% equity interest in SHPL, a company incorporated in Hong Kong with limited liability and a wholly-owned subsidiary of the Company and its subsidiaries, the lawful currency of Hong Kong, the Hong Kong Special Administrative Region of the People's Republic of China, Hong Kong Stock Exchange, The Stock Exchange of Hong Kong Limited, Listing Rules, the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (as amended and supplemented from time to time), Longstop Date, the date which is four months from the date of the Agreements (i.e. April 30, 2025) or, if extended in accordance with the Agreements, six months from the date of the Agreements (i.e. June 30, 2025) (or as mutually agreed in writing between the parties to the respective Agreement) the People's Republic of China, but for the purposes of this announcement only, except where the context requires, references to PRC or China exclude Hong Kong, Macau and Taiwan, Profit Guarantee Period, the years ending December 31, 2024, 2025, 2026 and 2027, Proposed Disposal, the proposed disposal of the GP Health Sale Shares pursuant to the GP Health SPA and the proposed disposal of the Shanghai Pharma Sale Shares pursuant to the Shanghai Pharma SPA, RMB, the lawful currency of the PRC, Sale Shares, collectively, the GP Health Sale Shares and the Shanghai Pharma Sale Shares, representing 45% equity interest in SHPL in aggregate, Seller, Shanghai HUTCHMED Investment (HK) Limited, a company incorporated in Hong Kong with limited liability and a wholly-owned subsidiary of the Company, Shanghai Pharma, Shanghai Pharmaceuticals Holding Co., Ltd.* (a) a joint stock company incorporated in the PRC with limited liability listed on the Shanghai Stock Exchange (stock code: 601607) and on the Main Board of the Hong Kong Stock Exchange (stock code: 02607), Shanghai Pharma Sale Shares, shares representing 10% equity interest in SHPL, the share purchase agreement dated December 31, 2024 entered into between the Seller and Shanghai Pharma in relation to the disposal of the Shanghai Pharma Sale Shares, Shanghai TCM, Shanghai Traditional Chinese Medicine Co., Ltd.* (a) a company established in the PRC with limited liability and a wholly-owned subsidiary of Shanghai Pharma, Shareholder(s), the holders of the shares of the Company, SHPL, Shanghai Hutchison Pharmaceuticals Limited, a company incorporated in the PRC with limited liability, Transition Period, three years from the date of Closing or until June 30, 2028, whichever is later, US\$, US dollars, the lawful currency of the United States of America, per cent. For identification purposes only, For the purpose of this announcement, the conversion of amounts in Renminbi into US dollars has been made at the rate of US\$1 to RMB7.36. The amounts in US dollars so converted are stated for reference only and the statement of those amounts should not be construed as a representation that amounts in Renminbi have been, or could be, converted into US dollars at this or any other rate. About HUTCHMED, HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with

its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. **Forward-Looking Statements** This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including, without limitation, statements concerning: HUTCHMED's future plans and prospects, its expectations as to the anticipated amount of proceeds, the intended use of proceeds, the anticipated closing date of the proposed transactions, and the therapeutic potential and clinical development of its R&D programs as well as the safety, efficacy, tolerability, scalability or combinability of all candidates under such programs. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the considerations, satisfaction of the conditions precedent to the consummation of the proposed transactions (including the ability of the parties to secure regulatory approvals on the terms expected, at all or in a timely manner), the ability of the parties to complete the proposed transaction, the continued sufficiency of preclinical and clinical data to support development and approval of the R&D programs in China, in the United States and in other jurisdictions, their potential to gain clinical trial approvals from regulatory authorities, the safety profile of the R&D programs, HUTCHMED's ability to fund, implement and complete its further clinical development and commercialization plans for the R&D programs, the timing of these events; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC programs; and HUTCHMED's ability to successfully develop and commercialize the R&D programs. In addition, when or if used herein, the words and phrases **aims**, **anticipates**, **believes**, **continue**, **estimates**, **expects**, **intends**, **may**, **on track**, **predicts**, **plans**, **potential**, **promising**, **should**, **to be**, **will**, and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Forward-looking statements are neither historical facts nor assurances of future performance. **Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM.** HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise. **Inside Information** This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018). **Order of the Board** **Edith Shih** Non-executive Director and Company Secretary **Hong Kong, January 1, 2025** **As at the date of this announcement, the Directors of the Company are:** **Chairman and Non-executive Director: Dr Dan ELDAR** **Executive Directors:** **Dr Weiguo SU** (Chief Executive Officer and Chief Scientific Officer) **Mr CHENG Chig Fung, Johnny** (Chief Financial Officer) **Non-executive Directors:** **Ms Edith SHIH** **Ms Ling YANG** **Independent Non-executive Directors:** **Mr Paul Rutherford CARTER** (Senior Independent Director) **Dr Renu BHATIA** **Dr Chaohong HUM** **Graeme Allan JACK** **Professor MOK Shu Kam, Tony** EX-99.3 4 hcm-20250102xex99d3.htm **EX-99.3** **Exhibit 99.3** **Press Release** **HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy** **Hong Kong, Shanghai & Florham Park, NJ** **Thursday, January 2, 2025:** HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/ AIM: HCM; HKEX: 13) today announces that the New Drug Application (NDA) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (TKI). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca. The NDA is supported by data from SACHI, a multi-center, open-label, randomized, controlled, Phase III trial which evaluated the efficacy and safety of a combination of ORPATHYS® and TAGRISSO® compared to platinum-based doublet-chemotherapy (pemetrexed plus cisplatin or carboplatin), the standard-of-care treatment option in this setting. The primary endpoint of the study was progression free survival (PFS) as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), time to response (TTR), and safety. The Independent Data Monitoring Committee (IDMC) of SACHI has considered that the study has met the pre-defined primary endpoint of PFS in a planned interim analysis and as a result, enrollment into the study has concluded. Results from SACHI will be submitted for presentation at an upcoming scientific conference (clinicaltrials.gov identifier NCT05015608). This marks the first regulatory filing for the ORPATHYS® and TAGRISSO® combination. The combination has demonstrated clear evidence to address MET-driven EGFR-inhibitor resistance and offers a continued path for oral treatment. said Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED. **With our biomarker-specific approach, we are hopeful to enhance treatment continuity and quality of life for NSCLC patients navigating this challenging journey. We and our partner AstraZeneca have been exploring this combination globally, through an array of late-stage clinical trials including the TATTON, SAVANNAH, SAFFRON and ORCHARD studies, and we hope to bring this all-oral, chemotherapy-free treatment option to patients with MET-driven lung cancer in the near future.** **The NMPA granted Breakthrough Therapy designation to the combination of ORPATHYS® and TAGRISSO® for this potential indication in December 2024.** The NMPA granted this designation to this combination as a new treatment that could target a serious condition where clinical evidence demonstrates substantial advantages over existing therapies. **About NSCLC and MET aberrations** Lung cancer is the leading cause of cancer death, accounting for about one-fifth of all cancer deaths. **1** Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC. **2** The majority of NSCLC patients (approximately

75%) are diagnosed with advanced disease, and approximately 10-15% of NSCLC patients in the US and Europe and 30-40% of patients in Asia have EGFR-mutated (â€œEGFRmâ€) NSCLC. 3,4,5,6 â€œâ€œMET is a tyrosine kinase receptor that has an essential role in normal cell development.7 MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is one of the mechanisms of acquired resistance to EGFR TKI for metastatic EGFR-mutated NSCLC. 7,8 Approximately 2-3% of NSCLC patients have tumors with MET exon 14 skipping alterations, a targetable mutation in the MET gene. 9 MET aberration is a major mechanism for acquired resistance to both first/second-generation EGFR TKIs as well as third-generation EGFR TKIs like osimertinib. Among patients who experience disease progression post-osimertinib treatment, approximately 15-50% present with MET aberration. 10,11,12,13,14 The prevalence of MET aberration depends on the sample type, detection method and assay thresholds used. 15â€ About ORPATHYS® and TAGRISSO® Combination Development in EGFR mutation-positive NSCLC The combination of ORPATHYS® and TAGRISSO® has been studied extensively in patients with EGFR mutation-positive NSCLC, including the TATTION (NCT02143466) and SAVANNAH (NCT03778229) studies. The encouraging results from these studies led to the initiation of three Phase III trials with this combination: SACHI (NCT05015608) and SANOVO (NCT05009836) were initiated in China in 2021, and the global, pivotal Phase III SAFFRON (NCT05261399) study started enrollment in 2022. In comparison to other treatment options, this combination treatment is chemotherapy-free, biomarker-specific and orally administered, aiming for a balanced efficacy, safety and quality-of-life profile for lung cancer patients.â€ SAVANNAH is a global Phase II study in patients who have progressed following osimertinib due to MET amplification or overexpression, and recruitment completed earlier in 2024. The evaluation of savolitinib in combination with osimertinib was designated as a Fast Track development program by the US Food and Drug Administration (FDA) in 2023. â€ SAFFRON is a multi-center, randomized, controlled, open-label, global Phase III trial in patients with EGFR mutation-positive NSCLC with MET overexpression and/or amplification after disease progression on osimertinib. â€ SACHI is a multi-center, randomized, controlled, open-label, China Phase III trial in patients with EGFR mutation-positive NSCLC with MET amplification after disease progression on any EGFR inhibitor therapy, including third-generation EGFR-TKIs such as osimertinib. â€ SANOVO is a multi-center, randomized, controlled, blinded, China Phase III trial in treatment-naâ€ve patients with EGFR mutation-positive NSCLC with MET-positive tumors.â€ About ORPATHYS® Approval in China ORPATHYS® was granted conditional approval in China for the treatment of patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. ORPATHYS® is the first selective MET inhibitor approved in China. It has been included in the National Reimbursement Drug List of China (NRDL) since March 2023. A supplementary NDA is under review which, if approved, could expand this indication to include treatment-naâ€ve adult patients in China. More than a third of the worldâ€™s lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.â€ About ORPATHYS® (savolitinib) ORPATHYS® is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.â€ ORPATHYS® is marketed in China and is currently under clinical development for multiple tumor types, including lung, kidney and gastric cancers, as a single treatment and in combination with other medicines.â€ In 2011, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to jointly develop and commercialize ORPATHYS®. Joint development of ORPATHYS® in China is led by HUTCHMED, while AstraZeneca leads development outside of China. HUTCHMED is responsible for the marketing authorization, manufacturing and supply of ORPATHYS® in China. AstraZeneca is responsible for the commercialization of ORPATHYS® in China and worldwide. Sales of ORPATHYS® are recognized by AstraZeneca.â€ About TAGRISSO® TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system (CNS) metastases. TAGRISSO® (40mg and 80mg once-daily oral tablets) has been used to treat nearly 800,000 patients across its indications worldwide and AstraZeneca continues to explore TAGRISSO® as a treatment for patients across multiple stages of EGFRm NSCLC. â€ There is an extensive body of evidence supporting the use of TAGRISSO® as standard of care in EGFRm NSCLC. TAGRISSO® improved patient outcomes in early-stage disease in the ADAURA Phase III trial, locally advanced disease in the LAURA Phase III trial, late-stage disease in the FLAURA Phase III trial, and with chemotherapy in the FLAURA2 Phase III trial. â€ About HUTCHMED HUTCHMED (Nasdaq/AIM:â€ HCM; HKEX:â€ 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.â€ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the â€œsafe harborâ€ provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMEDâ€™s current expectations regarding future events, including its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a studyâ€™s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of savolitinib for a targeted indication; and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as osimertinib as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMEDâ€™s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages,

or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.â€¢CONTACTSâ€¢Investor Enquiries+852Â 2121Â 8200 / ir@hutch-med.com â€¢â€¢Media Enquiriesâ€¢FTIÂ Consulting â€“+44Â 20Â 3727Â 1030Â / HUTCHMED@fticonsulting.comBen Atwell / Alex Shaw+44Â 7771Â 913Â 902Â (Mobile)Â / +44Â 7779Â 545Â 055Â (Mobile)Brunswick â€“ Zhou Yi+852Â 9783Â 6894Â (Mobile)Â / HUTCHMED@brunswickgroup.comâ€¢â€¢Panmure LiberumNominated Advisor and Joint BrokerAtholl TweedieÂ / Freddy CrossleyÂ / Rupert Dearden+44Â 20Â 7886Â 2500â€¢â€¢HSBCJoint BrokerSimon AlexanderÂ / Alina VaskinaÂ / Arnav Kapoor+44Â 20Â 7991Â 8888â€¢â€¢CavendishJoint BrokerGeoff NashÂ / Nigel Birks+44Â 20Â 7220Â 0500â€¢â€¢

REFERENCES1World Health Organization.

International Agency for Research on Cancer. All cancers fact sheet. Available at: <https://gco.iarc.fr/today/>Â -data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed November 2022.2American Cancer Society. What is Lung Cancer? Available at: <https://www.cancer.org/cancer/lung-cancer/about/what-is.html>. Accessed November 2022.3Knight SB, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070.4Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-27.5Zhang Y, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48).6Szumera-CieÄ‡kiewicz A, et al.â€¢EGFR Mutation Testing on Cytological and Histological Samples in 11. Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence.â€¢Int J Clin Exp Pathol. 2013;6:2800-12.7Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074).8Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. Journal of Hematology & Oncology. 2019;63.9Vuong HG, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer â€“ A systematic review and meta-analysis. Lung Cancer. 2018; 123: 76-82. 10Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125.11Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640.12Hartmaier R, et al. Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study. Cancer ResÂ 15 June 2022; 82 (12 Supplement):Â LB078.13Piotrowska, et al. MET amplification (amp) as a resistance mechanism to osimertinib. Journal of Clinical Oncology 2017 35:15 _suppl, 9020-9020. 14Hartmaier, et al. Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study. Cancer Res (2019) 79 (13_Supplement): 4897.15Coleman N, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2019;6(6). GRAPHIC 5 hcm-20250102xex99d1001.gif GRAPHIC begin 644 hcm-20250102xex99d1001.gif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end GRAPHIC 6 hcm-20250102xex99d2001.gif GRAPHIC begin 644 hcm-20250102xex99d2001.gif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end GRAPHIC 7 hcm-20250102xex99d3001.gif GRAPHIC begin 644 hcm-20250102xex99d3001.gif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

\$J 1D0!-: MS;FQ!(@D-MK%L->:03R)+HZ\$-[(BJC6G!"SH]2RQ)AXTO(@0+!%DZ\$2..M#. M!KHG4!-D#M ['KJ-
!\$5^JZJ=\$.=9CCX0#U"5+Y" M>LWN(*P*.E/\$UN:G-\GD M!=*: @.0&DB<1%2M.>9N1^%!7N(=:
=:B2ZN8,+YB07N+GL@R#\R\$AVD!\#, "5L MDPNA"E=X%".M9B44G-1#^,?"&J[0A0) 01K@MYH-Y(\$-'1L+_,@) A*& \$
M8U' %/PA9(JP'LIM*\$4?(P"J\$K *UBE[LR%]\2P(%C@,_95LCRKY)!X&0E M4]D4UY@M%UXQ=.T:
Q>UPI4@QDN,6!\$9R>(" ;>43(%L#*1=N6: %C@,2)@ M3(%8%Y9[,4,>#" NRE@"DH0XE4\$"3L" ^OD0K
H*YPO.LI0+T"/*4@N2+ M&0>&RE9J)(H=@25!ZK"X4! 7,X"\$J\$E#,!D4)/ON2_0@B)?U@A .'694R MHZ(J9<8/
*APP5,8CEG*G, 31#(V)19-H2DH7+R,U; Y++ A,2 @R3*GA'R M%J)I_>5/U'@C?Y\$IP2.B)
[.Z<(\$([+_R_7@+"\$[6IC1@*ZV@T3,LD\$T&G: MEP<"K>Y"![!-(&)RV+M-\$=']%A]3
&@0M,5O;6U3UE\B8(.#'\$%1P&/>A>0T MH@G02%(8',BSU!*&F17D#3T"3YT\N!%(T<<.>%C2'? P5#O8(:"K<@!]D92D
MTQ7\$/[1SZD!4ER763>H"3L-,F#0Z@)70@:CL VI5?I XI%'3B.%8AZTP!RU MQ""E\$K
;WO#)G3L, %:QVO>@690]@R0J+HS:9T,@M9X!O(8U S")8H9%<\5 M=#\@):KI\$(\$,_J6R)('>@@-,.+\$+ODB\$E=-C.L \$1#
#P(Y,+<:/&36"0#I M0!# O!JF@=A_WU2KGDCE@0BP-O=2N")%[I>G:(CM"7,307=^QXS\$6 ^@U#* MF9X# 9D"X
2\$W"\$!J3W ; [BT*J*K[(")>(+LIHL",VEH-2#%D02 E0<8.../2A#B,Y YH MZ,#52F.V[EIV@E(RD-IZX(4TP\$-\$-
:@#"%'BPI#\$9J&PPS8, 4<*A_;\$MM^Q5 M2 ,793<8M?0*,3" #CG5\AAV?
823[[2#@^+:\$&!++D3C4(<0BN2JOZU=VBD\$KR M +7](;,>0B+ NS%!=3II0XDH*0)\$J/!!T0
BWHB5Y<#>M6FOI_7J"0Q;;H ML1(D9@U",,)-\C" #D/UK>;3% QF.< 4Y-/O<)+&B4Z0=QP4@L8MX,(&[1] Q
M/(3EW64Y2"\@X:2D13=L ;U1J.=MG:_FXY@_I8^E5&/AH!9?"E"\!)>R!
ML]M=\$*X'1>0\$V_O<2U]A#@Y)ZYJ@=J71K_>G>UV9#P.]X[CPT'^<@\ M7\A\YL&00C1H_@N<'XCG/_+W7B!]&?
[O.I7_WDO5*T@('=-H_>G>L&,_=NZ\$A_#4-Q MR\$CD8(08%*Y!6&5_WH24'IB)G-5CG52 0XJD
S09RG'3" @SA<0S:YK/#B#@ M##.M*14+2(B:98(0' B45Z:4"G)0H"K\$%[S52]>5G(Q(7\$.@CTM(3QP,\T',X
MQ!\$#Q_<1D+(JY3<^"64I P%5)R\$Z^Y1A"H4!;V9KO4%8K5% (P XI4ZZI(E M 0!EB<5FVB1KM3)GYQ5.?
6)6([4%"6\$&T<,B]856AV,PD'9LO.4 ?'()@,*\$ MQ2&!S<%G&U\$S_..!I_%+G(8?M,-^0P,TAD<@&F95!4\$^!W(4E40\$[(4*80 M&9(DX302(94L))5?!>\$&+058]55 5]@0PO5 ,D\$&CV. (*<%'5\$Y6VA@T/5 M3%\$5):D%)K:"3
JE\$#V0/FN3\$&]X+ARU&UF57M#24J8T\$- 3%3-R\R+,VA MAS:2(C355R[&5CZB MF7\$943%5R8!T>R?^E7,3\$A-
"@()@=AB?4C/@4E%1:U M\$!K537)X7JNE%[]C@>UD:@G6(REE*\$DX+&J!A69S/>FT3S& (Q&@B!M1?_R' M
BP*A_0BP9R*0U%39%"%#55!-D8?:"4TC))W%C/"#\$@>0 >@CLJTCCR@ M*JLE3LI!"BT@(TFF'-7Q EN AX1H8W2B
BR@ AJID2O0D=9(!NHEBR<2 09(M(MC24X3%?Y;S!1EP-0/U.378ANTWB3)Y)6H 9. MDI!!&!K, <^@)WPXUW4 ;
<&%=M@HI6J!9U4G@5-%O]I2# SS)17<\$82 & MP@\$=P %B298:#9(U3-+%88G2(;%* "YHE7ZN%F_QXGJ0@
)9DN9<;D 9J M\ZZXCNP^"-Y8(07. 'H85L,>"&_(R(Q4 .0&9DU8 ,Q "1 1I+\E1#/#0T\1
M<'D:D9)*]7>G@0&;]9(>,"M04AGGQUF&1U7S@88#H2EIDYK^& #'EE6*XPFE MA8K XI3((@'2\$Y,%TH M9!"99B
_58;I YL"D4AP_WB;M?D_>Y2;-B **P(G(Z& *R(!# @2PXF\$ R\$G M^*2%"1%DT&%XQX.(:G&+CP*6B/\$>7OB28# K3(?
45",9-J;_E0##510B(MT%2>JU%>WH0F&[(VQP(H,58'="8W2B(F"D7(OD&[D5/@'\$%
M9<80JJ*+!J"4[8#^7,2^5\$!&*!95S,5N^B:6G404K IB84DRV02\$D)>YI4F M*5&
'EIF\IDWA,A2%EB%\$U!H6WH<%82*N\5;!O->T1,!^M01UO1/(D&:CT@0 M:H
\MA,/-8V:00G!,_X\$D0)5\$@JV)"!F!"6K:@L7)^M#(1]&%"+380O6)/ M,95F-L)2HO6E!0^ BM&24LK" A3(C=%R3YP9 2T
21^A Z(JJCN00CV0 Z.Z M \U5\$&"0 QJPCEF& 2A@!0R%\$V0 SL@JE33\$&' QY@ (JKDPP 2\$FX@K>JK5B@!68 H!\1\$ [
end